Richard Cathomas, MD, on MIBC: Perioperative Intravesical Recombinant BCG Combined With Chemoimmunotherapy

June 01, 2026 By The ASCO Post Staff

Richard Cathomas, MD, of Cantonal Hospital Graubünden, reviews results from the primary analysis of SAKK 06/19, an open-label single arm phase II trial, which found that the combination of intravesical recombinant bacillus Calmette-Guérin (BCG) with atezolizumab, cisplatin, and gemcitabine was feasible and safe without unexpected toxicities and demonstrates promising efficacy in patients with muscle-invasive bladder cancer (MIBC) (Abstract 4503).

Related Content